Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Letter to the Editor

Statins and Non-Alcoholic Fatty Liver Disease Progression: Further Comments

Author(s): Vasilios G. Athyros*, Charalambos Koumaras and George Sfikas

Volume 19 , Issue 6 , 2021

Published on: 15 December, 2020

Page: [673 - 674] Pages: 2

DOI: 10.2174/1570161119666201215141414

[1]
Sfikas G, Psallas M, Koumaras C, et al. Prevalence, diagnosis and treatment with 3 different statins of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in military personnel. Do genetics play a role? Curr Vasc Pharmacol 2021; 19(5): 572-81.
[http://dx.doi.org/10.2174/1570161118666201015152921] [PMID: 33059580]
[2]
Lee JI, Lee HW, Lee KS, Lee HS, Park JY. Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study. Am J Gastroenterol 2021; 116(1): 116-24.
[http://dx.doi.org/10.14309/ajg.0000000000000845] [PMID: 33027082]
[3]
Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376(9756): 1916-22.
[http://dx.doi.org/10.1016/S0140-6736(10)61272-X] [PMID: 21109302]
[4]
Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013; 168(4): 3846-52.
[http://dx.doi.org/10.1016/j.ijcard.2013.06.024] [PMID: 24001698]
[5]
Kargiotis K, Athyros VG, Giouleme O, et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 2015; 21(25): 7860-8.
[http://dx.doi.org/10.3748/wjg.v21.i25.7860] [PMID: 26167086]
[6]
Dongiovanni P, Petta S, Mannisto V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63(3): 705-12.
[http://dx.doi.org/10.1016/j.jhep.2015.05.006] [PMID: 25980762]
[7]
Kamal S, Khan MA, Seth A, et al. Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2017; 112(10): 1495-505.
[http://dx.doi.org/10.1038/ajg.2017.170] [PMID: 28585556]
[8]
Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017; 71: 17-32.
[http://dx.doi.org/10.1016/j.metabol.2017.02.014] [PMID: 28521870]
[9]
Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363(14): 1341-50.
[http://dx.doi.org/10.1056/NEJMra0912063] [PMID: 20879883]
[10]
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016; 59(6): 1121-40.
[http://dx.doi.org/10.1007/s00125-016-3902-y] [PMID: 27053230]

© 2022 Bentham Science Publishers | Privacy Policy